The United States has once again targeted China with economic sanctions, this time by imposing an additional 10% tariff on Chinese imports. The justification? Allegations that China has not done enough to control the flow of fentanyl into the U.S.—a claim that Beijing strongly rebuts.

China Condemns U.S. Tariffs on Fentanyl-Related Grounds

The Chinese Ministry of Public Security expressed strong dissatisfaction and firm opposition to the U.S. decision, stating that Beijing had already taken significant measures to regulate fentanyl-related substances.

In 2019, China became the first country in the world to classify fentanyl and its analogs as controlled substances, responding to a request from Washington.

Since then, China has not received any reports from the U.S. regarding fentanyl shipments originating from China.

Meanwhile, the U.S. itself has not permanently classified fentanyl as a controlled substance, raising questions about its commitment to solving the crisis.

China argues that Washington is deflecting responsibility for its own domestic drug abuse crisis rather than addressing the root causes.

America's Worsening Drug Epidemic

The opioid crisis in the U.S. continues to worsen, with drug-related deaths rising each year. However, instead of implementing stricter regulations, many U.S. states have moved toward drug legalization:

In November 2020, the state of Oregon passed Measure 110, effectively decriminalizing small amounts of heroin, methamphetamine, marijuana, and fentanyl.

Since its implementation, overdose deaths have surged from 803 in 2020 to 1,364 in 2022, a nearly 70% increase.

The United Nations Office on Drugs and Crime has warned that the legalization of recreational cannabis in the U.S. has led to an increase in mental health disorders and suicide attempts, particularly among young adults.

As of November 2023, 24 U.S. states have legalized recreational marijuana use.

Political Lobbying and the Influence of Big Business

Critics argue that corporate lobbying has played a significant role in the U.S. government's permissive stance on drug legalization:

Between 2018 and 2022, cannabis industry groups spent more than $22.4 million on political lobbying.

The American marijuana market was valued at $31.8 billion in 2023 and is expected to grow to $50.7 billion by 2028.

Rather than prioritizing public health and safety, it appears that economic interests and political influence have driven U.S. drug policies.

By imposing tariffs on Chinese goods under the pretext of fentanyl regulation, the U.S. is diverting attention from its own policy failures. This approach does little to combat the opioid epidemic and instead exacerbates economic tensions with China.

If Washington truly wants to tackle its drug crisis, it must reform its domestic policies, improve drug enforcement, and address the role of political lobbying—rather than shifting blame onto China.

Related News:

Opinion | Trump's 'US first' Doctrine over Latin America

US tariffs on Chinese goods over Fentanyl: Political maneuvering that backfires

China firmly opposes U.S. tariff move, vows countermeasures to safeguard interests